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G protein-coupled receptors (GPCRs) are a large family of cell-surface receptors that are Our next goal was to validate the SBA approach as a method to identify GPCR-RAMP 145 interactions without having to rely upon the use of epitope tags engineered into both the GPCR and 146 the RAMP. Thus, we needed to assess the available protein-specific Abs to each GPCR and each 147 RAMP, which were obtained from either commercial sources or HPA. In order to validate the utility 148 of each anti-RAMP Ab, the cell lysates containing epitope-tagged RAMPs were incubated with the 149 SBA, which included nine anti-RAMP Abs. The captured RAMPs were detected using the PE-150 conjugated OLLAS and PE-conjugated FLAG mAbs. We found that five out of the nine HPA and 
153
Validated Abs are underlined in table S1.
154
In parallel, the collection of anti-GPCR Abs was validated for GPCR capture using cell 155 lysates containing the 23 epitope-tagged GPCRs. In this case, the detection Abs used were anti-1D4 156 and anti-HA. When using either PE-conjugated anti-1D4 or PE-conjugated anti-HA as the detection through their native sequence, ablating the need to create epitope-tagged constructs. With few exceptions (<0.05%) the majority of signals associated with complex capture using the anti-GPCR
173
Abs that reached a Z-score ³ 1.645 were obtained from lysates containing the target GPCR.
174
We next determined whether the data obtained using anti-GPCR capture Abs recapitulated 175 the results obtained with the epitope-tag capture methods (table S3) . Overall, the statistical analysis 176 shows that the results obtained using anti-GPCR Abs to capture the GPCR-RAMP complex Detection of GPCR-RAMP complexes using an SBA assay 183 We used several detection and capture Ab pairs in a multiplexed fashion to identify GPCR-
184
RAMP complexes. The complexes were captured through epitope tags engineered onto the GPCR 185 or RAMP, and PE-conjugated anti-epitope tag mAbs were used to detect the putative interacting 
209
We compared PLA puncta count from cells that were co-transfected with CALCRL and 210 RAMP2. We observed a significant number of puncta under the PLA conditions when both 211 CALCRL and RAMP2 were co-expressed (Fig. 5A, fig. S7A and B). We verified that the puncta 212 were from plasma membrane interaction and not an artifact of misfolded protein accumulation in 213 the ER by employing a formaldehyde (FA)-based fixation method ( fig. S7C ). We next used PLA 214 to test GPCR-RAMP2 interactions in cell membranes for a variety of other GPCRs that were also 215 studied using SBA. We focused on quantifying interactions between RAMP2 and CALCRL, 216 PTH1R, GPR182, GPR4 and CXCR3. These GPCRs showed a range of capabilities to interact with 217 RAMP2 in the SBA under conditions of detergent solubilization. The PLA results indicated that 218 there were differences in puncta count among the receptor-RAMP2 pairs studied (Fig. 5B and C RAMPs (2, 3, 7-11) . However, we failed to observe one 
254
In addition, we discovered several new secretin-like GPCR-RAMP complexes that have not 255 been described previously. We found that GIPR and ADCYAP1R1 formed complexes with all three 
RAMP1
, suggesting that the complex should exist in the absence of ligand (32). The extensive contact surface between CALCRL and RAMP1 suggests that the complex should be stable under 294 conditions used here in the SBA assay. Given that the CALCRL-RAMP1 structure is generalizable 295 to other possible GPCR-RAMP complexes, Abs that would capture the GPCR through ECL2 might 296 fail to recognize the same GPCR in complex with a RAMP. In line with this hypothesis, we found 297 that a subset of validated anti-GPCR Abs were unable to capture a GPCR-RAMP complex that 298 were identified through capture using other Abs.
299
We validated a set of Abs to detect GPCR-RAMP complexes in order to avoid artifacts 300 inherent in having to rely upon insufficiently characterized Abs (33, 34) . Cross-reactivity of anti-
301
GPCR Abs is a particular problem due to structural and amino acid sequence similarity among GPCRs included in the study. We assessed Ab cross-reactivity even in the absence of the intended 305 GPCR while unintended GPCR targets were over-expressed. Using the SBA, we found at least one
306
Ab that targeted the intended GPCR with high selectivity for 19 of the 21 targets with HPA Abs 307 available. We also found at least one Ab to each RAMP that specifically captured the targeted 308 RAMP. Future experiments will validate additional anti-GPCR Abs as they become available. In 309 addition, the SBA strategy can be used to screen for therapeutic mAbs that show the lowest cross-310 reactivity with other GPCRs.
311
By being able to use protein-specific, anti-GPCR Abs in the multiplexed SBA assay, the 312 requirement to use engineered epitope tags and a heterologous overexpression system would be 313 eliminated. This would alleviate the potential of identifying non-physiological interactions, since 314 the requirement for overexpressing both proteins would be removed. Thus, we determined whether 315 anti-GPCR Abs can capture the GPCR-RAMP complexes directly. The pre-validated anti-GPCR
316
Abs used in the SBA were able to capture the majority of the GPCR-RAMP complexes as 317 demonstrated by using OLLAS mAb detection.
To our knowledge, no robust proteomics approaches are available to address GPCR-protein 
352
In summary, the multiplexed SBA assay we developed enables the validation and use of
353
Abs for the detection of GPCR-RAMP interactions. As a proof-of-concept, we defined the 354 complete interactome between secretin-family GPCRs and RAMPs (Fig. 4) . We also identified a 355 number of novel GPCR-RAMP interactions, including some interacting partners among 356 rhodopsin-family GPCRs that we selected for study based on earlier bioinformatics analysis. We 357 used the in situ PLA to verify the extent of the interaction between several GPCR-RAMP2 pairs 358 tested in the SBA. The SBA is scalable, allowing up to 500 beads to be conjugated with different
359
Abs and decoded in the Luminex system. Therefore, we intend to expand the existing SBA, which 360 consisted of 70 beads, based on the validation of additional Abs using epitope-tagged controls.
361
We also look forward to using the SBA strategy to study other protein-protein interactions,
362
including, but not limited to, GPCR heterodimerization. We consider the SBA technology to be 363 potentially transformative with respect to studies of membrane protein systems. Table S1 . The ID of the bead coupled to each specific Ab, the source of the Ab, and product code.
525 Table S2 . Statistical significance of GPCR-RAMP complex formation using epitope tags for 526 capture.
527 Table S3 . Overall statistic for GPCR-RAMP complex formation. anti-HA MFI shows maximum projection of Z-stack, which is the maximum signal intensity for each channel at No.
